Redeye states the Q3 report was strong across the board. The Company continues on its path of profitability with Gross profit-to-asset-ratio continuing to increase with higher revenue and gross margin. We adjust our estimates for Q4'22–Q4'23 and our fair value range.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.

Attachments

Gasporox - Keeping its Phot-on the Gas

© Modular Finance, source Nordic Press Releases